1 A new method of Non-Ultrasound Monitoring of Ovarian Stimulation

2 (NUMOS): Mission Possible! - a pilot study.

3

- 4 Iavor K. Vladimirov1,2, Desislava Tacheva1,2, Evan Gatev3, Magdalena Rangelova1, Martin Vladimirov 1
- 5 1 SBALAGRM-SOFIA, Sofia, Bulgaria,
- 6 2 Sofia University "St.Kliment Ohridski", Cytology- Histology and Embryology., Sofia, Bulgaria,
- 7 3 Bulgarian Academy of Science, Institute of Molecular Biology, Sofia, Bulgaria

8

9 Corresponding author: lavor K. Vladimirov – vladimirov@ivf.bg, address:5B, Baku str., Sofia 1700, Bulgaria.

10

11 Abstract:

Purpose: This study aims to establish the viability of monitoring an appropriate and safe ovarianstimulation without the use of ultrasound and serum hormone testing.

Method: As a primary marker for monitoring of the ovarian response, we used urinary estrone-3glucuronide (E1-3G) growth rate, which was self-measured by patients daily at home, with a portable analyzer, during the stimulation. For an adequate ovarian response, an average daily rate of increase of E1-3G was estimated to be within 25 - 77%. Ovulation trigger day was determined based on the length of the menstrual cycle.

- 19 The study included 24 women. Inclusion criteria were age < 41 years and AMH >1 ng/mL. A progestin-
- 20 primed ovarian stimulation protocol (PPOS) with fixed doses of gonadotropins was used.

21	Results: The average female age was 32,9 years (±4.4), BMI 22,7 kg/m2 (±4,3), AMH 3,7 ng/ml (±2,6),			
22	stimulation days 10,6 (±1,1), collected oocytes 12,5 (±8,5), MII oocytes 10,6 (±7,8), fertilization rate 83,6%			
23	(±22,5), blastocyst 66,4% (±28,6), good quality blastocysts 31,6% (±16,9).			
24	Absence of oocyte aspiration was found in one of the cases. There were no cases of OHSS and ovarian			
25	stimulation cancellation.			
26	Conclusion: This is the first pilot study to successfully apply a new markers for ovarian stimulation			
27	monitoring.			
28	Keywords: ovarian stimulation, monitoring, estrone-3-glucuronide, menstrual cycle length, progestin-			
29	primed ovarian stimulation protocol.			
30				
31	Introduction:			
31 32	Introduction: Ovarian stimulation (OS) is defined as a pharmacological treatment with the intention of inducing the			
32	Ovarian stimulation (OS) is defined as a pharmacological treatment with the intention of inducing the			
32 33	Ovarian stimulation (OS) is defined as a pharmacological treatment with the intention of inducing the development of more follicles in the ovaries, and consequently obtaining multiple oocytes by follicular			
32 33 34	Ovarian stimulation (OS) is defined as a pharmacological treatment with the intention of inducing the development of more follicles in the ovaries, and consequently obtaining multiple oocytes by follicular puncture (1). Control of ovarian stimulation (COS) is carried out through regular ultrasound			
32 33 34 35	Ovarian stimulation (OS) is defined as a pharmacological treatment with the intention of inducing the development of more follicles in the ovaries, and consequently obtaining multiple oocytes by follicular puncture (1). Control of ovarian stimulation (COS) is carried out through regular ultrasound examinations and blood sampling to monitor the dynamics of hormones. The main reasons for applying			
32 33 34 35 36	Ovarian stimulation (OS) is defined as a pharmacological treatment with the intention of inducing the development of more follicles in the ovaries, and consequently obtaining multiple oocytes by follicular puncture (1). Control of ovarian stimulation (COS) is carried out through regular ultrasound examinations and blood sampling to monitor the dynamics of hormones. The main reasons for applying COS are to induce the maximum number of mature oocytes, thereby increasing the chance of live birth;			
32 33 34 35 36 37	Ovarian stimulation (OS) is defined as a pharmacological treatment with the intention of inducing the development of more follicles in the ovaries, and consequently obtaining multiple oocytes by follicular puncture (1). Control of ovarian stimulation (COS) is carried out through regular ultrasound examinations and blood sampling to monitor the dynamics of hormones. The main reasons for applying COS are to induce the maximum number of mature oocytes, thereby increasing the chance of live birth; to determine the appropriate time to apply the so-called ovulation trigger for the final maturation of the			
32 33 34 35 36 37 38	Ovarian stimulation (OS) is defined as a pharmacological treatment with the intention of inducing the development of more follicles in the ovaries, and consequently obtaining multiple oocytes by follicular puncture (1). Control of ovarian stimulation (COS) is carried out through regular ultrasound examinations and blood sampling to monitor the dynamics of hormones. The main reasons for applying COS are to induce the maximum number of mature oocytes, thereby increasing the chance of live birth; to determine the appropriate time to apply the so-called ovulation trigger for the final maturation of the eggs and to prevent the risk of excessive ovarian response with ovarian hyperstimulation syndrome			
32 33 34 35 36 37 38 39	Ovarian stimulation (OS) is defined as a pharmacological treatment with the intention of inducing the development of more follicles in the ovaries, and consequently obtaining multiple oocytes by follicular puncture (1). Control of ovarian stimulation (COS) is carried out through regular ultrasound examinations and blood sampling to monitor the dynamics of hormones. The main reasons for applying COS are to induce the maximum number of mature oocytes, thereby increasing the chance of live birth; to determine the appropriate time to apply the so-called ovulation trigger for the final maturation of the eggs and to prevent the risk of excessive ovarian response with ovarian hyperstimulation syndrome (OHSS), a rare iatrogenic complication of COS (2). Frequent OS monitoring visits are costly and time-			

43	To reduce the visits for ultrasound examinations, new methods are being developed to manage ovarian
44	stimulation during in vitro treatment. They depend upon examining estrone-3-glucuronide levels in
45	urine (4,5) and salivary hormone oestradiol and progesterone measurements (6).
46	Currently, two main stimulation approaches have been developed: Self-Operated Endovaginal
40	currently, two main stimulation approaches have been developed. Sen-Operated Endovaginal
47	Telemonitoring /SOET/ (7) and Controlled Ovarian Stimulation Monitoring by Self-Determination of
48	Estrone-3-Glucuronide and Single Ultrasound (COSSESU). The implementation of these approaches is
49	carried out with the active participation of patients and with the assistance of some elements of
50	telemedicine (8). Some of the advantages that these two different approaches to ovarian stimulation
51	provide, are the reduction of: costs of regular ultrasound and hormone tests; stress gained due to
52	performing frequent blood tests in order to determine the values of different hormone levels in serum;
53	time wasted in frequent clinic visits and traveling; direct non-medical expenses related to the use of a
54	car, bus, train, hotel accommodation; food and risk of infection in situations similar to COVID-19.
55	The different approaches as described include elements of telemedicine. Even though many publications
56	have been made in regards to using telemedicine in cardiology, dermatology, diabetes, and general
57	practice, almost nothing has been reported regarding reproductive medicine. Interest has also increased
58	tremendously due to the recent COVID-19 pandemic. We support the notion that telemedicine has a
59	place in the treatment of infertility with the use of in vitro technologies (9).
60	This study aims to establish the viability of monitoring ovarian stimulation without the use of ultrasound
61	and serum hormone testing so that the stimulation is appropriate and safe. We called that new method
62	Non-Ultrasound Monitoring Ovarian Stimulation (NUMOS). Its main goal is to significantly reduce
63	patient visits during stimulation and their respective costs.

64

65 Materials and Methods

66 Patient Selection Criteria

- 67 All patients (n = 24) underwent COH and IVF/ICSI procedures at the clinic (Sofia IVF clinic, SBALAGRM-
- 68 SOFIA, Sofia, Bulgaria), during the period from November 2022 to January 2023. The study group of
- 69 patients applied the Freeze-all policy. Their embryos were cryopreserved for later FET without fresh ET.
- 70 All patients gave informed consent to participate in the program.
- 71 The study included 24 women with regular menstrual cycle (21-35 days) in 24 stimulated cycles.
- 72 Inclusion criteria were age < 41 years and AMH >1 ng/mL. Exclusion criteria: patients with a severe male
- 73 factor (spermatozoa <=1 million/ml), and endometriosis.

74 Method

75 A progestin-primed ovarian stimulation protocol (PPOS) with fixed doses of gonadotropins was used.

The starting doses were determined based on a preliminary assessment of the ovarian reserve, carried
out in the previous 3 months.

78 Control of the adequacy of the ovarian response was based on monitoring the stimulation, as per the 79 dynamics in the urine E3G ratio by regular determination of the E3G in the urine independently by the 80 patients in home conditions. This was done with a small portable analyzer, which was easy to use and 81 takes a short time to read E3G in the sample. The patient then sends the obtained result to the 82 attending physician through a platform created for this purpose. A portable urine E3G analyzer and test 83 strips were given to patients free of charge and patients received no compensation for participation. For 84 an adequate ovarian response, an average daily rate of increase of E1-3G was estimated to be within 25 85 - 77% (10). In parallel, ultrasound examinations were performed, as the results of the study were not 86 used to monitor the stimulation but were intended to minimize the risk to patients and the patient 87 worries.

Criteria for determining the day for ovulation trigger and follicular puncture were based on the length of	
the menstrual cycle. It was calculated on the base of average length of the natural menstrual cycle for	
the three previous months, without the use of hormonal drugs for stimulation or contraceptives. We	
assumed that the middle of the menstrual cycle +/- 1 day is the optimal day for follicular puncture.	
Consider the following example of the new approach: with a 28-day menstrual cycle, the middle is the	
14th day, respectively the ovulation trigger should be injected on the 12th day. If stimulation is started	
on day 2, then the number of stimulated days will be 10 days. If the stimulation is started from the 3rd	
day, then the number of stimulated days will be 9 days. In cycles longer than 30 days, stimulation lasts	
longer, with the day of follicular puncture being the 16th (+/- 1) day of the menstrual cycle.	
The deviation of one day was in accordance with the optimization of the work of the clinic related to the	
end of the week. The days of gonadotropin stimulation have no bearing on determining the day of	
follicular puncture.	
A GnRH-agonist (Decapeptyl, Ferring) was used to trigger ovulation and was administered 34-36 hours	
before the follicular puncture (Fig 1).	
Oocytes were fertilized by ICSI and all embryos were cultivated to blastocyst phase, and frozen.	
Statistical analysis:	
The ranges were determined based on quantile analysis.	
Results:	

- 107 The average female age was 32,9 years (±4.4), BMI 22,7 kg/m2 (±4,3), AMH 3,7 ng/ml (±2,6), stimulation
- 108 days 10,6 (±1,1), collected oocytes 12,5 (±8,5), MII oocytes 10,6 (±7,8), fertilization rate 83,6% (±22,5),
- 109 blastocyst formation 66,4% (±28,6), good quality blastocysts 31,6% (±16,9).
- 110 Absence of oocyte aspiration was found in one of the cases. There were no cases of OHSS and ovarian
- 111 stimulation cancellation.
- 112
- 113 Discussion:

114 Theoretical basis of the method.

- 115 The success of the method is based on the application of criteria and methods that aim for the ovarian
- response to be: 1) appropriate to the applied stimulation doses, 2) effective, i.e. aspiration of oocytes
- 117 sufficient in number and quality and 3) safe for the patients. The main factors on which the success of
- 118 ovarian stimulation and its effectiveness depend are as follows:
- 119 Choice of stimulation protocol.
- 120 The application of PPOS makes treatment more convenient for patients by replacing some subcutaneous
- 121 injections with oral medication.
- 122 The results of studies with different designs, different participant characteristics, and different
- 123 progestins have established high-quality evidence supporting the effectiveness of progestins in
- 124 obtaining similar numbers of oocytes with similar duration of stimulation and gonadotropin
- 125 consumption compared to other stimulation protocols (11).
- 126 On the other hand, Guan et al. (12) in a meta-analysis of randomized controlled trials found that the
- 127 number of oocytes retrieved, MII oocytes, and viable embryos was higher in PPOS protocols than in the

- 128 control protocol. Based on a systematic review and meta-analysis, other authors found more obtained
- embryos in the PPOS protocol compared to standard stimulation protocols (13).
- 130 Next, the administration of progestins to inhibit ovulation with ovarian stimulation has been shown to
- 131 be effective and safe with a low risk of OHSS. With the progestin protocol, the strategy of Freeze-all
- must be applied, in which case it is possible to apply a GnRH agonist as an ovulation trigger which
- 133 significantly reduces the risk of OHSS. (14)
- 134 The American Society for Reproductive Medicine states that the risk of OHSS is about 1-2% and can be
- 135 further reduced with the use of a GnRH agonist, triggering final oocyte maturation (15).
- 136 Ovulation triggering with a GnRH agonist almost completely eliminates the risk of OHSS without
- affecting oocyte and embryo quality and is therefore the trigger of choice. (16).
- 138 The above-mentioned advantages of the PPOS protocol and the possibility of administration of GnRH
- agonist as an ovulation trigger motivated our choice of the progestin protocol when applying the new
- 140 approach to control ovarian stimulation.

141 Determining the stimulation doses.

142 Various algorithms have been developed to determine the starting doses of gonadotropins. The 143 methods are based on preliminary determination of FSH and AMH levels, AFC, BMI, age, and history of smoking (17, 18, 19, 20,21). These algorithms for determining the initial stimulating doses aim for 144 145 aspiration of 8-15 oocytes and eliminating the risk of OHSS in GnRH-agonist and antagonist protocols 146 and performing the so-called fresh ET. In our new approach to ovarian stimulation control, we apply a 147 PPOS protocol with mandatory embryo freezing. In this case, miscalculation of the stimulating doses and 148 the use of higher ones did not affect the LBR in thawed ET, in contrast to fresh ET. On the other hand, 149 when applying the Freeze-all strategy with a GnRH-agonist as an ovulation trigger, it would be desirable

to aim for the retrieval of between 15 and 20 oocytes, which represents a good balance between safety

151 and efficacy(22, 23).

152 Monitoring the stimulation.

- 153 Monitoring of the stimulation is based on the growth rate of E3G in the urine through its regular
- determination, independently by the patients in home conditions. The method is based on a relatively
- high correlation of estrone-3-glucuronide (E1-3G) urinary levels, which are a function of increasing
- estradiol levels during stimulation (24,25,26,27). The correlation was also established using the specific
- 157 portable analyzer (4,10). Some components of the theoretical rationale developed by Vladimirov et al.
- 158 (8) for monitoring ovarian stimulation by determining urinary E3G were applied. An appropriate
- response is identified with growth dynamics within established limits (28).

160 Criteria for determining the day of follicular puncture.

161 Our proposed new algorithm for determining the day follicular puncture is based on a thorough analysis

162 of various scientific facts and regularities. We examined the relationship between the size of the

follicles, the duration of the stimulation, and the length of the menstrual cycle, as well as the maturity of

the oocytes, the quality of the embryos, and the success rate of the treatment.

165 A major method for predicting the possibility of aspiration of mature oocytes is the size of the follicles

166 during ovarian stimulation. It is known that metaphase II (mature) oocytes can be aspirated from

167 follicles of various sizes. In the literature, data on the ideal follicle size that determines the exact

168 moment to apply the ovulation trigger are conflicting. No universally accepted follicle size threshold has

- 169 been established to predict the presence of good competent oocytes. Overall, there is evidence that
- 170 follicles with an average diameter between 16 and 22 mm are those most likely to contain MII oocytes,
- 171 whereas small follicles rarely can generate MII oocytes. The frequency of mature oocytes increases with
- 172 follicle size (329), however, in both relatively small and very large follicles, non-metaphase II oocytes can

173 be aspirated. Mature oocytes are often aspirated from follicles larger than 16 mm in size. A greater 174 number of immature oocytes are found in follicles smaller than 12 mm, and some authors recommend 175 that such follicles should not be aspirated (30,31). Other authors found that mature oocytes can be 176 aspirated from follicles with a smaller diameter, respectively between 11 to 14 mm (32,33,34). 177 Regarding the size of the follicles and the development of the embryos after fertilization, no relationship 178 has been established because the results are contradictory (35,36). This suggests that the optimal follicle 179 size may be population-specific. 180 In other studies, the authors found that in oocytes obtained from smaller follicles, the degree of 181 polyspermy was higher after fertilization by conventional IVF, as well as a higher degree of 182 fragmentation was observed, associated with a lower pregnancy rate (30). These effects may be due to 183 reduced oocyte competence or due to safeguards against the entry of more than one spermatozoon and 184 development during subsequent cleavage stages. Other authors did not confirm differences in oocyte 185 maturation rate (35) or fertilization rate between small and large follicles. A mature oocyte can be 186 obtained from a follicle measuring between 12 and 24 mm. Oocytes can be in metaphase II 187 development, despite being derived from small follicles (0.3–0.9 mL volume), showing similar 188 fertilization capacity and rate of blastocyst formation compared to oocytes of larger follicles (1-6 mL and 189 >6 mL) (37). Some publications have demonstrated reduced fertilization rate and developmental 190 competence of oocytes derived from very large (>23 mm) follicles, indicating the adverse effects of 191 prolonged stimulation (38,39). 192 The facts presented above and our analysis give us reasons to believe that the size of the follicle from 193 which a mature oocyte with normal characteristics can be aspirated varies widely. On the other hand, 194 the main ultrasound criteria for determining an ovulation trigger, namely the presence of at least 3 195 follicles larger than 17 mm, also allows for a broader interpretation of the optimal day for follicular 196 puncture.

A number of authors have found that in the different protocols (long, antagonist or flare stimulation

197 The question arises, does the day of follicular puncture depend on the duration of stimulation?

198

199 protocol), the duration of ovarian stimulation has no negative effect on the success rate in IVF/ICSI 200 procedure (40). Optimal ovarian response and pregnancy outcome is associated with stimulation 201 duration between 9 -12 days (41). 202 Several authors have sought an answer to the question, whether changing the day for follicular puncture 203 by one day from the optimal one (determined by ultrasound), has a negative effect on the quality of 204 aspirated oocytes, respectively embryos and delivery rate. The purpose of the studies is to avoid 205 performing follicular punctures on the weekend, and the results are related to determining the success 206 rate based on fresh embryo transfer. Ben-Chetrit et al. (42) found that performing the follicular 207 puncture a day earlier or later had no negative effect on the success rate using a GnRH-analogues 208 protocol. Other authors have found that delaying hCG administration by 1 or 2 days does not worsen 209 results in regard to the agonist protocol. 210 Another study has found that in patients with fixed days of stimulation in a long protocol, success rates 211 were similar to those who had conventional ovarian stimulation monitoring (43). Similar results and 212 conclusions also have been reported by authors applying an antagonist protocol in ovarian stimulation. 213 Tremellen et al. (44) report that the early implementation of follicular puncture by 1 day from the 214 optimum, leads to a decrease in the number of aspirated oocytes and created embryos. Delaying 215 puncture by 1 day from optimal results in a non-significant increase in the number of oocytes collected 216 and embryos created. However, the implementation of follicular puncture with the deviation of a day 217 from the optimal one has no significant effect on the success rate based on live birth rates. The authors

report that in a retrospective analysis of a large, randomized clinical trial (Engage) a one-day delay in

HCG as an ovulation trigger does not negatively affect either the number of oocytes aspirated, or thepregnancy rate (45).

221 In support of the above studies (46,47,48,49) and the results of a meta-analysis of seven RCTs (50), the 222 authors suggest that a delay in follicular puncture within 1-2 days when using a GnRH-antagonist 223 protocol may result to aspiration of more mature oocytes without having an adverse effect on 224 implantation and ongoing pregnancy rate. Mirzachi et al. (16) in their systematic review, reported that: 225 moderate-quality evidence indicates that in freeze-all cycles, a moderate delay of 2–3 days in ovulation 226 triggering may result in the retrieval of an increased number of mature oocytes without impairing the 227 pregnancy rate. According to the authors, ovarian stimulation for frozen cycles is different in many 228 aspects from conventional stimulation for fresh IVF cycles. 229 It is clear from the above that the duration of ovarian stimulation with gonadotropins can be within 230 relatively wide limits, without having a negative effect on the quality of the oocytes, respectively 231 pregnancy and live births. 232 For this reason, we looked for another approach and the use of other parameters to determine the 233 ovulation trigger day and the follicular puncture day, respectively. 234 Already at the dawn of IVF technologies, a solution was sought through the so-called programmed 235 oocyte retrieval to find a method that does not use US monitoring of ovarian stimulation. The authors 236 used a predetermined day to apply an ovulation trigger without regard to the ovarian response. The 237 authors report that this ovarian stimulation approach was effective in the treatment of infertility 238 through the IVF procedure and was associated with significant practical and economic benefits (51, 239 52,53).

We hypothesized that the length of the menstrual cycle could be used to determine the duration ofovarian stimulation and that this would not negatively affect the success of the IVF procedure. It is

known that the length of the menstrual cycle has a relationship with the aging of the ovary and its
reserve (51). As ovarian function declines, the follicular phase is shortened, which is associated with
lower AMH and AFC and poor IVF outcomes (16). On the other hand, menstrual cycle length has

prognostic value for ovarian response in OS (54,55,56).

246 A study by Zhao et al. (57) remains in support of the thesis that the length of the menstrual cycle can be 247 successfully applied as a marker to determine the day of follicular puncture. The authors determine the 248 optimal day for triggering ovulation, based on determining the length of the follicular phase of the 249 menstrual cycle. They define it as the difference between the length of the menstrual cycle and the 250 length of the luteal phase, which is 14 days. 6,110 women with regular menstrual cycles were included 251 in the study. From the analysis of the different groups, it can be seen that the days of stimulation vary 252 between 8-12 days. A significant difference was found in the number of oocytes, fertilizations, embryos, 253 and embryos of good quality in the different groups of patients, but this was not observed in 254 comparisons based on pregnancies and births. The Q3 group, which has the best success rates, has an 255 OS/FP (ovarian stimulation/follicular phase) ratio of 0.67-0.77. After analysis, it is evident that with a 256 regular 28-day cycle, in the Q3 group, stimulation varying from 9 to 11 can be included, which are 257 relatively wide limits.

258 Ours is the first pilot study to successfully apply a new approach to ovarian stimulation monitoring 259 without the use of ultrasound and hormone analysis. This new method of monitoring and controlling 260 ovarian stimulation based on other criteria such as the dynamics in the levels of E1-3G in urine and the 261 length of the menstrual cycle. The in-depth analysis of the results of the studies, as well as our 262 experience in using E1-3G in urine as a marker for the effectiveness of ovarian stimulation, motivated us 263 to develop and successfully implement this new approach for monitoring the stimulation. The method 264 can successfully replace the classical approach of monitoring stimulation through regular ultrasound 265 examinations and analysis of serum hormone levels.

266 Limitations:

267	This study has some limitations. First, it is necessary to apply the method to a larger group of patients.	
268	Next, it is also necessary address the question, is this approach applicable only to the Freeze-all strategy	
269	or is it also possible to apply it with protocols that allow the implementation of fresh ET?	
270	Conclusion:	
271	This is a new approach for stimulation monitoring and does not exclude the use of standard methods. Its	
272	main goal is reducing patient visits during stimulation, respectively direct and indirect costs in IVF	
273	treatment.	
274	In recent decades, we have witnessed the introduction of new technologies into assisted reproduction.	
275	The entry of artificial intelligence and telemedicine is already a fact. Established perceptions and	
276	approaches about how to control ovarian stimulation are constantly evolving. The development of new	
277	stimulation protocols and different strategies enables a look into a new era of IVF in the 21st century.	
278	The new ovarian stimulation monitoring method developed and successfully implemented by us is part	
279	of this future. A two visits IVF treatment (TV/IVF) approach is now a reality, through which we will	
280	reduce the direct and indirect costs of infertility treatment. The current technology allows it!	
281	Data Availability Statement	

- The raw data supporting the conclusions of this article will be made available by the authors, without
- 283 undue reservation.

284 Ethics Statement

285	The studies involving human participants were reviewed and approved by the Ethics Committee of the			
286	SBALAGRM-SOFIA hospital. Informed consent for participation was written patients did not receive any			
287	compensation for participation.			
288	Data sharing statement: Consent to share data was not obtained thus individual patient data will not be			
289	shared.			
290	Author Contributions:			
291	IKV: Design, conception, analysis and interpretation of data, drafting of article, writing - review &			
292	editing, supervision. DT: Design, drafting of article, funding acquisition. MR: Acquisition of data, design.			
293	IG: Analysis and interpretation of data, writing - review & editing, visualization. MV: Conception, writing			
294	- review & editing, visualization. All authors approved the final manuscript. All authors contributed to			
295	the article and approved the submitted version.			
296	Funding -NA			
296 297	Funding -NA Conflict of Interest			
297	Conflict of Interest			
297 298	Conflict of Interest The authors declare that the research was conducted in the absence of any commercial or financial			
297 298 299	Conflict of Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.			
297 298 299 300	Conflict of Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments:			
297 298 299 300 301	Conflict of Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Acknowledgments: The authors would like to thank all the medical staff in the SBALAGRM-SOFIA for their assistance in data			

Le KD, Vuong LN, Ho TM, Dang VQ, Pham TD, Pham CT, et al. A cost-effectiveness analysis of
 freeze only or fresh embryo transfer in IVF of non-PCOS women. Human Reproduction.

307 2018;33(10):1907-1914

Wu AK, Elliott P, Katz PP, Smith JF. Time costs of fertility care: The hidden hardship of building a
 family. Fertility and Sterility. 2013; 99:2025-2030. DOI: 10.1016/j.fertnstert.2013.01.145

310 3. Kelly J, Hughes CM, Harrison RF. The hidden costs of IVF. Irish Medical Journal. 2006; 99:142-143

4. Vladimirov I, Martin V, T Desislava T. Urine estrone–3-glucuronide (E3G) assay: Is there any

place during ovarian stimulation for IVF cycles? Human Reproduction, Volume 36, Issue Supplement_1,

deab130.669, 2021

5. Hart RJ, D'Hooghe T, Dancet EAF, Aurell R, Lunenfeld B, Orvieto R, et al. Self-monitoring of

urinary hormones in combination with telemedicine - a timely review and opinion piece in medically

316 assisted reproduction. Reproductive Sciences. 2021; 29:1-14. DOI: 10.1007/s43032-021-00754-5

317 6. Sakkas D, Howles CML, Atkinson L, Borini A, Bosch EA, Bryce C, et al. A multi-Centre

318 international study of salivary hormone Oestradiol and progesterone measurements in ART monitoring.

319 Reproductive Biomedicine Online. 2020; 42:421-428

320 7. Gerris J, Annick DA, Dhont N, Frank VF, Madoc B, Magaly BM, et al. Self-operated Endovaginal

321 Telemonitoring versus traditional monitoring of ovarian stimulation in assisted reproduction: An RCT.

322 Human Reproduction. 2014; 29:1941-1948. DOI: 10.1093/humrep/deu168

323 8. Vladimirov IK, Vladimirov M, Tacheva D. A new protocol for controlled ovarian stimulation

324 monitoring by self-determination of Estrone-3-glucuronide and single ultrasound (COSSESU). Open

journal of Obstetrics and Gynecology. 2021; 11:1217-1228

326 9. Berg WT, Goldstein M, Melnick AP, Rosenwaks Z. Clinical implications of telemedicine for

327 providers and patients. Fertility and Sterility. 2020;114(6):1129-1134. DOI:

328 10.1016/j.fertnstert.2020.10.048.

329 10. Vladimirov I K, Tacheva D, Gatev E, Rangelov M and Vladimirov M. Viability of home monitoring

of estrone-3-glucuronide (E1-3G) urine levels in controlled ovarian stimulation: A pilot study. Human

Reproduction, Volume 38, Issue Supplement_1, June 2023, dead093.932,

332 https://doi.org/10.1093/humrep/dead093.93230.

11. Ata B, Capuzzo M, Turkgeldi E, Yildiz S, La Marca A. Progestins for pituitary suppression during

334 ovarian stimulation for ART: a comprehensive and systematic review including meta-analyses. Hum

Reprod Update. 2021 Jan 4;27(1):48-66. doi: 10.1093/humupd/dmaa040.

336 12. Guan S, Feng Y, Huang Y and Huang J. Progestin-Primed Ovarian Stimulation Protocol for

337 Patients in Assisted Reproductive Technology: A Meta-Analysis of Randomized Controlled Trials. Front

338 Endocrinol (Lausanne). 2021 Aug 31;12: 702558. doi: 10.3389/fendo.2021.702558. eCollection 2021.

13. Cui L, Lin Y, Wang F, Chen C. Effectiveness of progesterone-primed ovarian stimulation in

340 assisted reproductive technology: a systematic review and meta-analysis. Arch Gynecol Obstet. 2021

341 Mar;303(3):615-630. doi: 10.1007/s00404-020-05939-y. Epub 2021 Jan 12.

14. La Marca A and Capuzzo M. Use of progestins to inhibit spontaneous ovulation during ovarian

stimulation: the beginning of a new era? Reprod Biomed Online. 2019 Aug;39(2):321-331. doi:

344 10.1016/j.rbmo.2019.03.212. Epub 2019 Mar 29.

345 15. Practice Committee of the American Society for Reproductive Medicine and Practice Committee

of the Society for Assisted Reproductive Technology. Repetitive oocyte donation: a committee opinion.

347 Fertil Steril 2014; 102:964–966.

348	16.	Mizrachi Y, Horowitz E, Farhi J, Raziel A and Weissman A. Ovarian stimulation for freeze-all IVF			
349	cycles:	a systematic review. Human Reproduction Update, Vol.26, No.1, pp. 119–136, 2020.			
350	17.	Popovic-Todorovic B, Loft A, Bredkjæer HE, Bangsbøll S, Nielsen IK, Andersen AN. A prospective			
351	randon	nized clinical trial comparing an individual dose of recombinant FSH based on predictive factors			
352	versus a 'standard' dose of 150 IU/day in 'standard' patients undergoing IVF/ICSI treatment. Human				
353	Reprod	l. 2003;18(11):2275–2282.			
354	18.	Popovic-Todorovic B, Loft A, Lindhard A, Bangsbøll S, Andersson AM, Andersen AN. A			
355	prospe	ctive study of predictive factors of ovarian response in 'standard' IVF/ICSI patients treated with			
356	recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Human Reprod.				
357	2003;18(4):781–787.				
358	19.	Howles CM, Saunders H, Alam V, Engrand P. Predictive factors and a corresponding treatment			
359	algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle				
360	stimulating hormone (Follitropin alfa) during assisted reproduction technology (ART) procedures. An				
361	analysi	s of 1378 patients. Curr Med Res Opin. 2006;22(5):907–918.			
362	20.	Olivennes F, Howles CM, Borini A, et al. Individualizing FSH dose for assisted reproduction using			
363	a novel	algorithm: the CONSORT study. Reprod Biomed Online. 2009;18(2):195–204.			
364	21.	Yovich JL, Alsbjerg B, Conceicao JL, Hinchliffe PM, Keane KN. PIVET rFSH dosing algorithms for			
365	individ	ualized controlled ovarian stimulation enables optimized pregnancy productivity rates and			
366	avoidance of ovarian hyperstimulation syndrome. Drug Des Devel Ther. 2016 Aug 10;10: 2561-73. doi:				
367	10.214	7/DDDT.S104104. eCollection 2016.			
368	22.	Gerber RS, Fazzari M, Kappy M, Cohen A, Galperin S, Lieman H, et al Differential Impact of			
369	Contro	lled Ovarian Hyperstimulation on Live Birth Rate in Fresh Versus Frozen Embryo Transfer Cycles: A			

370 Society for Assisted Reproductive Technology Clinic Outcome System Study. Fertil Steril (2020)

371 114:1225–31.

372 23. Munch EM, Sparks AE, Zimmerman MB, Van Voorhis BJ, Duran EH. High FSH dosing is associated

373 with reduced live birth rate in fresh but not subsequent frozen embryo transfers. Hum Reprod 2017;32:

374 1402–1409.

375 24. Rapi S, Fuzzi B, Mannelli M, Pratesi S, Criscuoli L, Pellegrini S, et al. Estrone 3-glucuronide

376 chemiluminescence immunoassay (LIA) and 17beta estradiol radioimmunoassay (RIA) in the monitoring

of superovulation for in vitro fertilization (IVF): correlation with follicular parameters and oocyte

378 maturity. Acta Eur Fertil. 1992;23(2):63–8

25. Catalan R, Castellanos JM, Palomino T, Senti M, Antolin M, Galard RM. Correlation between

380 plasma estradiol and estrone3-glucuronide in urine during the monitoring of ovarian induction

381 therapy. Int J Fertil. 1989;34(4):271–5.

382 26. Alper MM, Halvorson L, Lasley B, Mortola J. Relationship between urinary estrone conjugates as

measured by enzyme immunoassay and serum estradiol in women receiving gonadotropins for in vitro
 fertilization. J Assist Reprod Genet. 1994;11(8):405–8.

385 27. Gary S. Nakhuda, Ning Li, Zheng Yang, Sylvia Kang. At-home urine estrone-3-glucuronide
386 quantification predicts oocyte retrieval outcomes comparably to serum estradiol. FS Rep 2023 Jan
387 28;4(1):43-48.

388 28. Simonetti S, Veeck LL, Jones HW Jr. Correlation of follicular fluid volume with oocyte morphology
389 from follicles stimulated by human menopausal gonadotropin. Fertil Steril. 1985;44(2):177–80.

Bergh C, Broden H, Lundin K, Hamberger L. Comparison of fertilization, cleavage and pregnancy
rates of oocytes from large and small follicles. Hum Reprod. 1998;13(7):1912–5.

30. Rosen MP, Shen S, Dobson AT, Rinaudo PF, McCulloch CE, Cedars MI. A quantitative assessment
of follicle size on oocyte developmental competence. Fertil Steril. 2008;90(3):684–90.
31. Scott RT, Toner JP, Muasher SJ, Oehninger S, Robinson S, Rosenwaks Z. Follicle-stimulating
hormone levels on cycle day 3 are predictive of in vitro fertilization outcome. Fertil Steril.

396 1989;51(4):651–4.

397 32. Mehri S, Levi Setti PE, Greco K, Sakkas D, Martinez G, Patrizio P. Correlation between follicular

398 diameters and flushing versus no flushing on oocyte maturity, fertilization rate and embryo quality. J

399 Assist Reprod Genet. 2014;31(1):73–7.

400 33. Akbariasbagh F, Lorzadeh N, Azmoodeh A, Ghaseminejad A, Mohamadpoor J, Kazemirad S.

401 Association among diameter and volume of follicles, oocyte maturity, and competence in

402 intracytoplasmic sperm injection cycles. Minerva Ginecol. 2015;67:397–403.

403 34. Salha O, Nugent D, Dada T, Kaufmann S, Levett S, Jenner L, Lui S, Sharma V. The relationship

404 between follicular fluid aspirate volume and oocyte maturity in in-vitro fertilization cycles. Hum Reprod.
405 1998;13:1901–16.

406 35. Nogueira D, Friedler S, Schachter M, Raziel A, Ron-El R, Smitz J. Oocyte maturity and

407 preimplantation development in relation to follicle diameter in gonadotropin-releasing hormone agonist
408 or antagonist treatments. Fertil Steril. 2006;85:578–83.

409 36. Haines CJ, Emes AL. The relationship between follicle diameter, fertilization rate, and
410 microscopic embryo quality. Fertil Steril. 1991;55:205–7.

411 37. Raine-Fenning N, Deb S, Jayaprakasan K, Clewes J, Hopkisson J, Campbell B. Timing of oocyte

412 maturation and egg collection during controlled ovarian stimulation: a randomized controlled trial

413 evaluating manual and automated measurements of follicle diameter. Fertil Steril. 2010;94:184–8.

414 38. Ectors FJ, Vanderzwalmen P, Van Hoeck J, Nijs M, Verhaegen G, Delvigne A, Schoysman R, Leroy

- 415 F. Relationship of human follicular diameter with oocyte fertilization and development after in-vitro
- 416 fertilization or intracytoplasmic sperm injection. Hum Reprod. 1997;12:2002–5.
- 417 39. Wertheimer A, Nagar R, Oron G, Meizner I, Fisch B, Ben-Haroush A. Fertility treatment outcomes
- 418 after follicle tracking with standard 2-dimensional sonography versus 3-dimensional sonography-based
- 419 automated volume count: prospective study. J Ultrasound Med. 2018;37(4):859–66.
- 420 40. Purandare N, Emerson G, Kirkham C, Harrity C, Walsh D, Mocanu E. The duration of
- 421 gonadotropin stimulation does not alter the clinical pregnancy rate in IVF or ICSI cycles. Ir J Med Sci
- 422 (2017) 186:653–657.
- 423 41. Sarkar P, Ying L, Plosker S, Mayer J, Ying Y, Imudia AN. Duration of ovarian stimulation is

424 predictive of in-vitro fertilization outcomes. Minerva Ginecol. 2019 Dec;71(6):419-426. doi:

425 10.23736/S0026-4784.19.04455-1. Epub 2019 Nov 13.

426 42. Ben-Chetrit, A., Senoz, S., Greenblatt, E.M., 1997. In vitro fertilization programmed for weekday427 only oocyte harvest: analysis of outcome based on actual retrieval day. J. Assist. Reprod. Genet. 14, 26–
428 31.

429 43. Nakagawa, K., Yamano, S., Senuma, M., Myogo, K., Yamazaki, J., Aono, T., 1997. Avoidance of
430 oocyte retrieval on the weekend through the use of scheduled ovarian hyperstimulation for in vitro
431 fertilization and embryo transfer. Fertil. Steril. 68, 787–79.

432 44. Tremellen, K.P., Lane, M., 2010. Avoidance of weekend oocyte retrievals during GnRH antagonist
433 treatment by simple advancement or delay of hCG administration does not adversely affectIVF live birth
434 outcomes. Hum. Reprod. 25, 1219–1224.

435 45. Levy MJ, Ledger W, Kolibianakis EM, Ijzerman-Boon PC, GordonIs K. it possible to reduce the 436 incidence of weekend oocyte retrievals in GnRH antagonist protocols? Reprod Biomed Online. 2013

437 Jan;26(1):50-8. doi: 10.1016/j.rbmo.2012.09.014. Epub 2012 Sep 26.

438 46. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Prolongation

439 of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles

440 stimulated with recombinant follicle-stimulating hormone and gonadotropinreleasing hormone

441 antagonists. Fertil Steril 2004;82:102–107.

442 47. Kolibianakis EM, Bourgain C, Papanikolaou EG, Camus M, Tournaye H, Van Steirteghem AC,

443 Devroey P. Prolongation of follicular phase by delaying hCG administration results in a higher incidence

444 of endometrial advancement on the day of oocyte retrieval in GnRH antagonist cycles. Hum Reprod

445 2005;20:2453–2456.

446 48. Morley L, Tang T, Yasmin E, Hamzeh R, Rutherford AJ, Balen AH. Timing of human chorionic

447 gonadotrophin (hCG) hormone administration in IVF protocols using GnRH antagonists: a randomized

448 controlled trial. Hum Fertil (Camb) 2012;15:134–139.

449 49. Levy MJ, Ledger W, Kolibianakis EM, Ijzerman-Boon PC, Gordon K. Is it possible to reduce the
450 incidence of weekend oocyte retrievals in GnRH antagonist protocols? Reprod Biomed Online
451 2013;26:50–58.

452 50. Chen Y, Zhang Y, Hu M, Liu X, Qi H. Timing of human chorionic gonadotropin (hCG) hormone
453 administration in IVF/ICSI protocols using GnRH agonist or antagonists: a systematic review and
454 metaanalysis. Gynecol Endocrinol 2014;30:431–437.

455 51. Vassena R, Vidal R, Coll O, Vernaeve V. Menstrual Cycle Length in Reproductive Age Women Is

456 an Indicator of Oocyte Quality and a Candidate Marker of Ovarian Reserve. Eur J Obstet Gynecol Reprod

- 457 Biol (2014) 177:130–4. doi: 10.1016/j.ejogrb.2014.03.027
- 458 52 Braude P R, Bright M V, Douglas C P, Milton P J, Robinson R E, Williamson J G, Hutchison J. A

459 regimen for obtaining mature human oocytes from donors for research into human fertilization in vitro.

460 Fertil Steril. 1984 Jul;42(1):34-8.

461 53. Frydman R, Rainhorn J D, Forman R, Belaisch-Allart J, Fernandez H, Lassalle B, Testart J.

462 Programmed oocyte retrieval during routine laparoscopy and embryo cryopreservation for later transfer

463 Am J Obstet Gynecol. 1986 Jul;155(1):112-7. doi: 10.1016/0002-9378(86)90091-8.

464 5. Frydman R, Forman R, Rainhorn J D, Belaisch-Allart J, Hazout A, Testart J. A new approach to

465 follicular stimulation for in vitro fertilization: programed oocyte retrieval Fertil Steril. 1986

466 Oct;46(4):657-62. doi: 10.1016/s0015-0282(16)49644-5.

467 54. Gizzo S, Andrisani A, Noventa M, Quaranta M, Esposito F, Armanini D, et al. . Menstrual Cycle

468 Length: A Surrogate Measure of Reproductive Health Capable of Improving the Accuracy of

469 Biochemical/Sonographical Ovarian Reserve Test in Estimating the Reproductive Chances of Women

470 Referred to ART. Reprod Biol Endocrinol (2015) 13:28. doi: 10.1186/s12958-015-0024

471 55. Younis JS, Iskander R, Fauser BCJM, Izhaki I. Does an Association Exist Between Menstrual Cycle

472 Length Within the Normal Range and Ovarian Reserve Biomarkers During the Reproductive Years? A

473 Systematic Review and Meta-Analysis. Hum Reprod Update (2020) 26:904–28. doi:

474 10.1093/humupd/dmaa013

- 475 56. Oehninger S, Nelson SM, Verweij P, Stegmann BJ. Predictive Factors for Ovarian Response in a
- 476 Corifollitropin Alfa/GnRH Antagonist Protocol for Controlled Ovarian Stimulation in IVF/ICSI Cycles.
- 477 Reprod Biol Endocrinol (2015) 13:117. doi: 10.1186/s12958-015-0113-1.
- 478 57. Xinyang Zhao, Xu Zhang, Shanshan Wu, Jichun Tan. Association Between the Ratio of Ovarian
- 479 Stimulation Duration to Original Follicular Phase Length and In Vitro Fertilization Outcomes: A Novel
- 480 Index to Optimise Clinical Trigger Time Front Endocrinol (Lausanne) . 2022 Jul 25;13:862500. doi:
- 481 10.3389/fendo.2022.862500. eCollection 2022.
- 482

483






Fig. 1. Non-Ultrasound Monitoring of Ovarian Stimulation (NUMOS)

medRxiv preprint doi: https://doi.org/10.1101/2023.10.26.23297609; this version posted October 27, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

